2. HPI
• 67 year old female presents with RUQ pain following large meals. She
states that the pain is crampy and colicky and moderate in severity.
• She also complains of diarrhea for the past 2 weeks.
• Past Medical History: Type II diabetes mellitus, hyperlipidemia,
hypertension, atrial fibrillation, diabetic neuropathy
• Past Surgical History: No previous surgery
• Allergies: PCN
• Medications: amlodipine, benazepril, aspirin, atorvastatin, carvedilol,
levemir, gabapentin, ranitidine
• Family History: Not significant
• Social History: Denies alcohol, tobacco, and illicit drugs.
3. PHYSICAL EXAM
• Vitals: Temp: 36.9ºC, HR: 67 bpm, BP: 172/85 mmHg
• General: Alert and oriented x4
• HEENT: Normocephalic, atraumatic. Extraocular movements intact,,
normal conjunctiva. No pharyngeal erythema.
• Respiratory: Lungs are clear to auscultation bilaterally. Breaths are
unlabored.
• Cardiovascular: RRR, symmetric pulses in all extremities.
• Gastrointestinal: RUQ pain on palpation. No masses, soft, non-
distended. Normal bowel sounds.
• Neurologic: CN II-XII intact
11. PHEOCHROMOCYTOMA
• Catecholamine-secreting tumors that arise from chromaffin cells of the
adrenal medulla
• Catecholamine-secreting tumors originate outside the adrenal medulla are
paragangliomas (sympathetic or parasympathetic nervous system)
• Occur in approximately 0.8/100,000 (underestimation as many are only
found at autopsy)
• Most occur in the fourth or fifth decade of life
• Patients present in 1 of 4 ways: classic, ”pheo crisis,” as an incidental finding,
or during screening for genetic or familial disease
• 40% are found as an incidental finding
12. CLASSIC
• Classic Triad: headache, palpitations,
sweating (40%)
• Hypertension (continuous or episodic)
(some patients present with normal
blood pressure)
• Difficulty breathing
• Weakness
• Panic attack-type symptoms
• Less common symptoms:
• Pallor, low blood pressure, blurred vision,
weight loss, increased thirst and urination,
constipation, abdominal pain, elevated
blood sugar, psychiatric disturbances,
cardiomyopathy
• 10% of patients
• Life-threatening release of
catecholamines
• Stroke
• Heart attack
• Organ failure
• Coma
• Death
“PHEO CRISIS”
PRESENTATION
13. RULE OF 10
• 10% Familial
• 10% Bilateral
• 10% in Children
• 10% Malignant
• 10% Extraadrenal
• 10% Not Associated with Hypertension
• 10% Contain Calcification
14. GENETIC/FAMILIAL DISEASE
• Family history of pheochromocytoma
• Multiple endocrine neoplasia, type II
• Von Hippel-Lindau
• Familial paraganglioma
• Neurofibromatosis 1
15. RADIOLOGIC FINDINGS
• Ultrasound
• Variable appearance from solid, solid to cystic, or mixed cystic
• CT
• Usually the initial modality
• Appear as heterogeneous masses with areas of necrosis and cystic change
• Avidly enhancing on arterial phase (more so than an adenoma)
• 110 HU enhancement or more on arterial phase indicates pheochromocytoma
• MRI
• T1: hypointense
• T2: markedly hyperintense (lightbulb sign)
• MIBG
• Neuroendocrine tumors have uptake on MIBG scan
16. TREATMENT
• Alpha-adrenergic blockers are given for 10-14 days (longer for certain
indications such as cardiomyopathy, recent MI, or resistant
hypertension) prior to surgical resection
• Phenoxybenzamine is the preferred agent
• Beta-adrenergic blockers should be given 2-3 days preoperatively
• Surgical resection with close monitoring of BP and heart rhythm
• Laproscopic adrenalectomy is preferred if there are no malignant features on
imaging
• Glucocorticoids should be given preoperatively if bilateral
adrenalectomy is planned
• Long term monitoring is necessary due to recurrence and metastatic
disease (which can be found many years after surgery)
17. REFERENCES
• Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and
primary aldosteronism. Rev Endocr Metab Disord 2007; 8:309.
• Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and
paraganglioma: an endocrine society clinical practice guideline. J Clin
Endocrinol Metab 2014; 99:1915.
• Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects of perioperative alpha1
block on haemodynamic control during laparoscopic surgery for
phaeochromocytoma. Br J Anaesth 2004; 92:512.
• Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of
pheochromocytoma. J Am Coll Surg 2009; 209:727.
• Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich)
2002; 4:62.
• Ros PR, Mortele KJ. CT and MRI of the abdomen and pelvis, a teaching file.
Lippincott Williams & Wilkins. (2006) ISBN:0781772370.
• Pacak K, Eisenhofer G, Lenders JW. Pheochromocytoma, Diagnosis,
Localization, and Treatment. Wiley-Blackwell. (2007) ISBN:1405149507.
Notas del editor
1. Choledocholithiasis and cholelithiasis with intrahepatic and extra
hepatic biliary ductal dilatation but without sonographic evidence of
acute cholecystitis.
2. Incidental right adrenal mass which is incompletely characterized
by ultrasound. (Superior to the right kidney in the area of the adrenal gland there is
a well-circumscribed, heterogenous mass which measures 4.8 x 6.3 x 6.0
cm. This mass has internal vascularity.)
Risk of malignancy is increased with masses larger than 4 cm
There is a large heterogeneous enhancing mass within the right adrenal
gland. The mass measures 5.6 x 5.1 x 5.8 cm. There is significant
enhancement with arterial phase and although there is washout on
delayed phase the mass is highly suspicious for neoplasm or
metabolically active adrenal adenoma. Consultation with surgical
urology is recommended. Left adrenal gland contains a small nodule in
the body of the gland.
1. Large heterogeneous enhancing right adrenal mass consultation with
surgical urology is recommended.
Absolute washout of 60% or higher or relative washout of 40% or higher is consistent with an adenoma. However, it has been reported that a non-calcified, non-hemorrhagic lesion with precontrast attenuation of more than 43 HU is suspicious for malignancy regardless of washout characteristics. Note that the marked enhancement raises the possibility of a pheochromocytoma.
Intense uptake in the large right adrenal pheochromocytoma. Milder
focal uptake in the left adrenal nodule suggests a second
neuroendocrine tumor in this region.
No evidence of regional or distant metastasis.
metaiodobenzylguanidine labeled to Iodine-123 or Iodine-131
Positive in neuroblastoma, paraganglioma, pheochromocytoma, carcinoid tumor, ganglioneuroma, ganglioneuroblastoma, medullary thyroid carcinoma
Some mild uptake can be physiologic in:
Liver, salivary glands, urinary bladder, heart, gastrointestinal tract, adrenal glands, brown fat